These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35475626)

  • 1. Fecal Microbial Community Composition in Myeloproliferative Neoplasm Patients Is Associated with an Inflammatory State.
    Oliver A; El Alaoui K; Haunschild C; Avelar-Barragan J; Mendez Luque LF; Whiteson K; Fleischman AG
    Microbiol Spectr; 2022 Jun; 10(3):e0003222. PubMed ID: 35475626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age-related macular degeneration and myeloproliferative neoplasms - A common pathway.
    Liisborg C
    Acta Ophthalmol; 2022 Oct; 100 Suppl 271(Suppl 271):3-35. PubMed ID: 36200281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing the microbiome of patients with myeloproliferative neoplasms during a Mediterranean diet intervention.
    Avelar-Barragan J; Mendez Luque LF; Nguyen J; Nguyen H; Odegaard AO; Fleischman AG; Whiteson KL
    mBio; 2023 Dec; 14(6):e0230823. PubMed ID: 37877698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms.
    Mendez Luque LF; Blackmon AL; Ramanathan G; Fleischman AG
    Curr Hematol Malig Rep; 2019 Jun; 14(3):145-153. PubMed ID: 31119475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence.
    Mendez Luque LF; Avelar-Barragan J; Nguyen H; Nguyen J; Soyfer EM; Liu J; Chen JH; Mehrotra N; Huang X; Kosiorek HE; Dueck A; Himstead A; Heide E; Lem M; El Alaoui K; Mas E; Scherber RM; Mesa RA; Whiteson KL; Odegaard A; Fleischman AG
    Cancer Res Commun; 2024 Mar; 4(3):660-670. PubMed ID: 38391189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm.
    Wang JC; Kundra A; Andrei M; Baptiste S; Chen C; Wong C; Sindhu H
    Leuk Res; 2016 Apr; 43():39-43. PubMed ID: 26943702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Microenvironment in Myeloproliferative Neoplasms.
    Ramanathan G; Fleischman AG
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):205-216. PubMed ID: 33641864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Microbiome and Metabolome of Preterm Infant Stool Are Personalized and Not Driven by Health Outcomes, Including Necrotizing Enterocolitis and Late-Onset Sepsis.
    Wandro S; Osborne S; Enriquez C; Bixby C; Arrieta A; Whiteson K
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Pathogenesis of Myeloproliferative Neoplasms.
    Rolles B; Mullally A
    Curr Hematol Malig Rep; 2022 Dec; 17(6):319-329. PubMed ID: 36336766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloproliferative neoplasm stem cells.
    Mead AJ; Mullally A
    Blood; 2017 Mar; 129(12):1607-1616. PubMed ID: 28159736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.
    Yu J; Parasuraman S; Paranagama D; Bai A; Naim A; Dubinski D; Mesa R
    BMC Cancer; 2018 Apr; 18(1):420. PubMed ID: 29653557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammation and myeloproliferative neoplasms.
    Lussana F; Rambaldi A
    J Autoimmun; 2017 Dec; 85():58-63. PubMed ID: 28669446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms.
    Büttner-Herold M; Sticht C; Wiech T; Porubsky S
    Histopathology; 2021 Apr; 78(5):738-748. PubMed ID: 33078472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.
    Koschmieder S; Mughal TI; Hasselbalch HC; Barosi G; Valent P; Kiladjian JJ; Jeryczynski G; Gisslinger H; Jutzi JS; Pahl HL; Hehlmann R; Maria Vannucchi A; Cervantes F; Silver RT; Barbui T
    Leukemia; 2016 May; 30(5):1018-24. PubMed ID: 26854026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs.
    Emanuel RM; Dueck AC; Geyer HL; Kiladjian JJ; Slot S; Zweegman S; te Boekhorst PA; Commandeur S; Schouten HC; Sackmann F; Kerguelen Fuentes A; Hernández-Maraver D; Pahl HL; Griesshammer M; Stegelmann F; Doehner K; Lehmann T; Bonatz K; Reiter A; Boyer F; Etienne G; Ianotto JC; Ranta D; Roy L; Cahn JY; Harrison CN; Radia D; Muxi P; Maldonado N; Besses C; Cervantes F; Johansson PL; Barbui T; Barosi G; Vannucchi AM; Passamonti F; Andreasson B; Ferrari ML; Rambaldi A; Samuelsson J; Birgegard G; Tefferi A; Mesa RA
    J Clin Oncol; 2012 Nov; 30(33):4098-103. PubMed ID: 23071245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells.
    Bao EL; Nandakumar SK; Liao X; Bick AG; Karjalainen J; Tabaka M; Gan OI; Havulinna AS; Kiiskinen TTJ; Lareau CA; de Lapuente Portilla AL; Li B; Emdin C; Codd V; Nelson CP; Walker CJ; Churchhouse C; de la Chapelle A; Klein DE; Nilsson B; Wilson PWF; Cho K; Pyarajan S; Gaziano JM; Samani NJ; ; ; Regev A; Palotie A; Neale BM; Dick JE; Natarajan P; O'Donnell CJ; Daly MJ; Milyavsky M; Kathiresan S; Sankaran VG
    Nature; 2020 Oct; 586(7831):769-775. PubMed ID: 33057200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey.
    Yu J; Paranagama D; Geyer HL; Parasuraman S; Mesa R
    Ann Hematol; 2019 May; 98(5):1119-1125. PubMed ID: 30694363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TLR4 and RAGE conversely mediate pro-inflammatory S100A8/9-mediated inhibition of proliferation-linked signaling in myeloproliferative neoplasms.
    Kovačić M; Mitrović-Ajtić O; Beleslin-Čokić B; Djikić D; Subotički T; Diklić M; Leković D; Gotić M; Mossuz P; Čokić VP
    Cell Oncol (Dordr); 2018 Oct; 41(5):541-553. PubMed ID: 29946821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased plasma nicotinamide phosphoribosyltransferase is associated with a hyperproliferative phenotype and restrains disease progression in MPN-associated myelofibrosis.
    Rosti V; Campanelli R; Massa M; Viarengo G; Villani L; Poletto V; Bonetti E; Catarsi P; Magrini U; Grolla AA; Travelli C; Genazzani AA; Barosi G
    Am J Hematol; 2016 Jul; 91(7):709-13. PubMed ID: 27074203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.